| ZMapp reduces diffusion of Ebola viral particles in fresh human cervicovaginal mucus A Schaefer, B Yang, HA Schroeder, D Harit, MS Humphry, L Zeitlin, ... Emerging Microbes & Infections 13 (1), 2352520, 2024 | | 2024 |
| Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial KW Chew, BO Taiwo, C Moser, ES Daar, DA Wohl, J Ritz, AC Javan, JZ Li, ... The Journal of Infectious Diseases, jiae369, 2024 | | 2024 |
| Health and economic impacts of Lassa vaccination campaigns in West Africa DRM Smith, J Turner, P Fahr, LA Attfield, PR Bessell, CA Donnelly, ... medRxiv, 2024 | | 2024 |
| Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival WA Fischer, DA Wohl The Lancet Infectious Diseases 24 (6), 560-562, 2024 | 1 | 2024 |
| Ebola Virus–Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort NG Bond, KR Shore, EJ Engel, EE Coonan, F Al-Hasan, MA Gbakie, ... The Journal of Infectious Diseases, jiae155, 2024 | | 2024 |
| Development and Pilot of an Mpox Severity Scoring System J Zucker, J McLean, S Huang, C DeLaurentis, S Gunaratne, K Stoeckle, ... The Journal of Infectious Diseases 229 (Supplement_2), S229-S233, 2024 | 3 | 2024 |
| COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina HI Henderson, DA Wohl, WA Fischer, LA Bartelt, D van Duin, DM Agil, ... Journal of Antimicrobial Chemotherapy 79 (4), 859-867, 2024 | | 2024 |
| Tecovirimat for Mpox—Promise and Limitations J Zucker, WA Fischer, T Wilkin JAMA Internal Medicine 184 (3), 279-280, 2024 | | 2024 |
| Projecting health and economic impacts of Lassa vaccination campaigns in West Africa DRM Smith, J Turner, P Fahr, LA Attfield, PR Bessell, CA Donnelly, ... medRxiv, 2024.02. 26.24303394, 2024 | | 2024 |
| Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial P Jagannathan, KW Chew, MJ Giganti, MD Hughes, C Moser, MJ Main, ... EClinicalMedicine 65, 2023 | 3 | 2023 |
| Association between anterior nasal and plasma SARS-CoV-2 RNA levels and hospitalization or death in nonhospitalized adults with mild-to-moderate COVID-19 MJ Giganti, KW Chew, JJ Eron, JZ Li, M Pinilla, C Moser, AC Javan, ... The Journal of Infectious Diseases 228 (Supplement_2), S117-S125, 2023 | 5 | 2023 |
| Creation and impact of containment units with high-risk zones during the coronavirus disease 2019 (COVID-19) pandemic NA Schnell, B Brewer, K Young, TS Brown, SS Carson, L Culp, ... Infection Control & Hospital Epidemiology 44 (6), 908-914, 2023 | 2 | 2023 |
| The Kinetics of Blood-soluble Mediators in Hospitalized COVID-19 Patients Infected With the Omicron Variant Compared to the Alpha Variant L Appleton, K Jakharia, CH Lu, B Sines, MB Drummond, WA Fischer, ... C45. COVID AND ITS CONSEQUENCES: PART II, A5119-A5119, 2023 | | 2023 |
| Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in nonhospitalized patients with COVID-19 TH Evering, KW Chew, MJ Giganti, C Moser, M Pinilla, DA Wohl, ... Annals of internal medicine 176 (5), 658-666, 2023 | 18 | 2023 |
| Safety and efficacy of combined tixagevimab and cilgavimab administered intramuscularly or intravenously in nonhospitalized patients with COVID-19: 2 randomized clinical trials RAB Ignacio, KW Chew, C Moser, JS Currier, JJ Eron, AC Javan, ... JAMA Network Open 6 (4), e2310039-e2310039, 2023 | 6 | 2023 |
| A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research … S Penfold, AA Adegnika, D Asogun, O Ayodeji, BN Azuogu, WA Fischer, ... PloS one 18 (3), e0283643, 2023 | 5 | 2023 |
| Safety and efficacy of inhaled interferon-Β1A (SNG001) in outpatients with COVID-19 P Jagannathan, KW Chew, M Giganti Top Antivir Med 69, 70, 2023 | 2 | 2023 |
| Post-Ebola symptoms 7 years after infection: the natural history of long Ebola DA Wohl, WA Fischer, W Mei, F Zou, S Tozay, E Reeves, K Pewu, ... Clinical Infectious Diseases 76 (3), e835-e840, 2023 | 9 | 2023 |
| The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19 TP Sheahan, LJ Stevens, TM Narowski, TJ Krajewski, C Lee, KR Mollan, ... medRxiv, 2023.11. 21.23298766, 2023 | 1 | 2023 |
| Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 KW Chew, C Moser, ES Daar, DA Wohl, JZ Li, RW Coombs, J Ritz, ... nature communications 14, 2023 | 2 | 2023 |
